Acrylic Acid

Acrylic Acid

SCHEMBL6133499

C=CC(=O)O.CCCCC(CC)CN

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.64
TDP1 Q9NUW8 2/20 0.64
TSHR P16473 3/20 0.54
CA2 P00918 6/20 0.44
MAPK1 P28482 1/20 0.41
CYP3A4 P08684 5/20 0.41
ATM Q13315 1/20 0.41
CA1 P00915 2/20 0.40
ACHE P22303 1/20 0.38
BACE1 P56817 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
SLC1A3 P43003 1/20 0.36
SLC1A2 P43004 1/20 0.36
SLC1A1 P43005 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acrylic Acid SCHEMBL29102608 0.91 ALDH1A1 (0.53) ALDH1A1TDP1TSHRCA2MAPK1
Bicarbonate SCHEMBL909943 0.87 ALDH1A1 (0.78) ALDH1A1TDP1TSHRCA2MAPK1
Carbamic Acid SCHEMBL28700287 0.85 ALDH1A1 (0.75) ALDH1A1TDP1TSHRCA2MAPK1
Acetic Acid SCHEMBL1878883 0.85 ALDH1A1 (0.75) ALDH1A1TDP1TSHRCA2MAPK1
Acrylic Acid SCHEMBL1741910 0.84 TSHR (0.56) ALDH1A1TDP1TSHRCA2MAPK1
Acrylic Acid SCHEMBL4448295 0.84 TSHR (0.56) ALDH1A1TDP1TSHRCA2MAPK1
Acrylic Acid SCHEMBL3835470 0.84 ALDH1A1 (0.67) ALDH1A1TDP1TSHRCA2MAPK1
Succinic Acid SCHEMBL5468972 0.81 TDP1 (0.69) ALDH1A1TDP1TSHRCA2MAPK1
Acrylic Acid Methyl Ester SCHEMBL15418484 0.81 TSHR (0.57) ALDH1A1TDP1TSHRCA2CYP3A4
Formic Acid SCHEMBL28548084 0.81 ALDH1A1 (0.75) ALDH1A1TDP1TSHRCA2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100441179-C Transdermal administration of (r)-3,3-diphenylpropylamine monoesters. SANOL ARZNEI SCHWARZ GMBH (DE) 2008-12-10 CN disclosed
CN-1767820-A Transdermal administration of (r)-3,3-diphenylpropylamine monoesters. SANOL ARZNEI SCHWARZ GMBH (DE) 2006-05-03 CN disclosed
US-20050226919-A1 Device for transdermal administration for the treatment of urinary tract disorders UCB PHARMA GMBH (DE) 2005-10-13 US disclosed
EP-1293198-B1 Device for transdermal administration for the treatment of urinary tract disorders SANOL ARZNEI SCHWARZ GMBH (DE) 2005-02-09 EP disclosed
WO-2003024432-A2 DEVICE FOR TRANSDERMAL ADMINISTRATION FOR THE TREATMENT OF URINARY TRACT DISORDERS SCHWARZ PHARMA AG (DE) 2003-03-27 WO disclosed
EP-1293198-A1 Device for transdermal administration for the treatment of urinary tract disorders SCHWARZ PHARMA AG (DE) 2003-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050226919-A1 Device for transdermal administration for the treatment of urinary tract disorders AR, CYP17A1, TACR1 ALDH1A1 1928/4885TDP1 4163/4885TSHR 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.